The REMEDEE Trial A Randomized Comparison of a Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stent With a Paclitaxel-Eluting Stent
Michael Haude, Stephen WL Lee, Stephen G Worthley, Sigmund Silber, Stefan Verheye, Sandra Erbs, Mohd Ali Rosli, Roberto Botelho, Ian Meredith, Kui Hian Sim, Pieter R Stella, Huay-Cheem Tan, Robert Whitbourn, Sukumaran Thambar, Alexandre Abizaid, Tian Hai Koh, Peter Den Heijer, Helen Parise, Ecaterina Cristea, Akiko Maehara Show all
JACC Cardiovascular Interventions | ELSEVIER SCIENCE INC | Published : 2013
OBJECTIVES: This study sought to compare the efficacy and safety results after coronary implantation of a combined sirolimus-eluting CD34 antibody coated Combo stent (OrbusNeich Medical, Ft. Lauderdale, Florida) with the paclitaxel-eluting Taxus Liberté stent (PES) (Boston Scientific, Natick, Massachusetts). This report summarizes the first-in-man randomized, controlled multicenter REMEDEE trial (Randomized study to Evaluate the safety and effectiveness of an abluMinal sirolimus coatED bio-Engineered StEnt) angiographic, intravascular ultrasound, and clinical results up to 12 months. BACKGROUND: Drug-eluting stents have limited restenosis and reintervention but are complicated by especially ..View full abstract
OrbusNeich Medical, Inc. provided the funding to conduct the REMEDEE trial. Dr. Haude has received support from Abbott, Biotronik, OrbusNeich, Medtronic, and Volcano. Dr. Meredith serves as a consultant to Boston Scientific and Medtronic. Dr. Maehara has received speaker's fees from St. Jude Medical; and research grant support from Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.